First Time Loading...

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 1 099.5 USD 1.78%
Updated: Jul 12, 2024
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note

Intrinsic Value

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. [ Read More ]

The intrinsic value of one REGN stock under the Base Case scenario is 506.36 USD. Compared to the current market price of 1 099.5 USD, Regeneron Pharmaceuticals Inc is Overvalued by 54%.

Key Points:
REGN Intrinsic Value
Base Case
506.36 USD
Overvaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Regeneron Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling REGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Regeneron Shows Strong Start with Promising Pipeline
Earnings Call Summary

Regeneron Shows Strong Start with Promising Pipeline

Regeneron Pharmaceuticals had a robust beginning in 2024, with first-quarter revenues rising 7% to $3.1 billion, driven by growth in Dupixent and Libtayo. The company's Dupixent sales reached $3.1 billion, representing a 24% increase. EYLEA HD netted $200 million, showing promise in retinal disease treatment. Regeneron anticipates FDA approval for Dupixent for COPD in June, potentially transforming treatment for 300,000 patients. Linvoseltamab, a potential best-in-class for late-stage myeloma, faces an August FDA decision. The firm also launched a $3 billion share repurchase program, emphasizing its commitment to returning capital to shareholders.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc

Current Assets 18.9B
Cash & Short-Term Investments 10.5B
Receivables 5.2B
Other Current Assets 3.1B
Non-Current Assets 15.5B
Long-Term Investments 7B
PP&E 4.2B
Intangibles 1.1B
Other Non-Current Assets 3.2B
Current Liabilities 3.6B
Accounts Payable 671.3m
Accrued Liabilities 2.4B
Other Current Liabilities 516.7m
Non-Current Liabilities 3.8B
Long-Term Debt 2.7B
Other Non-Current Liabilities 1.1B
Efficiency

Earnings Waterfall
Regeneron Pharmaceuticals Inc

Revenue
13.1B USD
Cost of Revenue
-1.8B USD
Gross Profit
11.3B USD
Operating Expenses
-7.3B USD
Operating Income
4B USD
Other Expenses
-146.4m USD
Net Income
3.9B USD

Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

REGN Profitability Score
Profitability Due Diligence

Regeneron Pharmaceuticals Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
71/100
Profitability
Score

Regeneron Pharmaceuticals Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

REGN Solvency Score
Solvency Due Diligence

Regeneron Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Regeneron Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 1 086.95 USD with a low forecast of 727.2 USD and a high forecast of 1 290.45 USD.

Lowest
Price Target
727.2 USD
34% Downside
Average
Price Target
1 086.95 USD
1% Downside
Highest
Price Target
1 290.45 USD
17% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

REGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

REGN Price
Regeneron Pharmaceuticals Inc

1M 1M
+7%
6M 6M
+18%
1Y 1Y
+53%
3Y 3Y
+92%
5Y 5Y
+276%
10Y 10Y
+246%
Annual Price Range
1 099.5
52w Low
718.42
52w High
1 099.5
Price Metrics
Average Annual Return 25.43%
Standard Deviation of Annual Returns 7.09%
Max Drawdown -13%
Shares Statistics
Market Capitalization 120.7B USD
Shares Outstanding 110 190 000
Percentage of Shares Shorted 1.77%

REGN Return Decomposition
Main factors of price return

What is price return decomposition?

REGN News

Other Videos

Last Important Events
Regeneron Pharmaceuticals Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Regeneron Pharmaceuticals Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

120.7B USD

Dividend Yield

0%

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The firm's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.

Contact

NEW YORK
Tarrytown
777 Old Saw Mill River Rd
+19148477000.0
https://www.regeneron.com/

IPO

1991-04-02

Employees

10 368

Officers

Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, President, Chief Scientific Officer & Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D.
Executive Vice President of Research
Dr. Andrew J. Murphy Ph.D.
Executive VP and GM of Industrial Operations & Product Supply
Mr. Daniel P. Van Plew
Executive Vice President of Commercial
Ms. Marion E. McCourt
Senior VP of Finance & CFO
Mr. Christopher R. Fenimore CPA
Show More
Senior Vice President of Quality Assurance & Operations
Ms. Patrice Gilooly
Senior VP of IT & Chief Information Officer
Mr. Bob McCowan
Senior Vice President of Investor Relations & Strategic Analysis
Mr. Ryan Crowe
Executive VP, General Counsel & Secretary
Mr. Joseph J. LaRosa
Show Less

See Also

Discover More
What is the Intrinsic Value of one REGN stock?

The intrinsic value of one REGN stock under the Base Case scenario is 506.36 USD.

Is REGN stock undervalued or overvalued?

Compared to the current market price of 1 099.5 USD, Regeneron Pharmaceuticals Inc is Overvalued by 54%.